Stockreport

Inotrem Unveils Game-Changing Precision Medicine Strategy for Nangibotide Clinical Development in Septic Shock [Yahoo! Finance]

ROCHE HOLDING LTD S/ADR  (RHHBY) 
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
PDF Published in Intensive Care Medicine, Inotrem's results highlight the pivotal role of the soluble TREM-1 biomarker in identifying high-risk septic shock patients and gu [Read more]